Shark Mitigation Systems now ASX listed

Published 16-MAY-2016 09:32 A.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

After raising $3.5 million from Australian capital markets to list on the ASX, Shark Mitigation Systems (ASX:SM8) made a successful debut on the exchange.

In partnership with Google and Optus, Shark Mitigation Systems are commercialising two shark deterrent technologies known as SAMS (Shark Attack Mitigation Systems) and Clever Buoy.

With the help of the University of Western Australia’s Oceans Institute and School of Animal Biology, Shark Mitigation Systems has developed its SAMS technology enabling the manufacture of marine apparel which can reduce the risk of shark attack, based on recently developed science of shark vision, neurology and behavioural effects.

The technology has been tested in wetsuits and is already available in wetsuits and surfboards, but has the potential to extend to skins and stickers for diving air tanks, diving fins, surfboards, kayaks, skis, watercraft, undersea cabling, and marine equipment.

SM8 doesn’t manufacture the wetsuits, it licenses technology into existing apparel from manufacturers such as Arena and Radiator.

The wetsuits are already available for sale through licensee and distribution agreements and an international roll-out is earmarked for this US$800MN (AU$1092MN) market.

Clever Buoy is a different type of technology with a similar focus.

Clever Buoy, already trialled at Bondi Beach, is a unique form of sonar detection technology that can detect sharks and other marine life without the need for tags or tracking devices.

The technology used for the Clever Buoy system utilises the ocean life version of facial recognition to detect sharks and other marine life. It is designed to operate completely autonomously, distinguishing large sharks from other species, and send a warning signal to lifeguards onshore.

The proprietary sonar technology has been developed in partnership with Optus, but SM8 also has backing from major corporate entities including early stage funding partner Google, as well as M&C Saatchi, Tritech and Deloitte.

With the proliferation of shark attacks on Australian shores, the technology couldn’t have come at a better time.

Discussion of whether to cull sharks or hunt down offending creatures may now dissipate somewhat and swimmer, suffers and general beachgoers could feel a little safer in the water.

Prior to listing SM8 co-founder Craig Anderson outlined the near-term ambitions for the company saying, “Listing on the ASX will provide SM8 with access to capital which will significantly assist the Company in advancing its technologies.

“We are actively pursuing further licensing agreements for our SAMS technology. We are also looking forward to progressing Clever Buoy into commercialisation following our highly successful deployment at Bondi Beach, with the technology anticipated to have broad market appeal with groups including local governments, private beach resorts and the aquaculture industry.”

SM8 received a strong investor response to its Initial Public Offering, securing $3.5 million through the placement of 17.5 million shares valued at $0.20 per share.

At market open today, SM8 was trading at $0.24 per share.

The past performance of this product is not and should not be taken as an indication of future performance. Caution should be exercised in assessing past performance. This product, like all other financial products, is subject to market forces and unpredictable events that may adversely affect future performance.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X